Monlunabant

Monlunabant (INV-202, MRI-1891, or S-MRI-1891) is a peripherally selective cannabinoid receptor 1 inverse agonist, discovered as a β-arrestin-2-biased cannabinoid receptor 1 antagonist by Dr George Kunos, Dr Resat Cinar, and Dr Malliga Iyer at the National Institutes of Health.^[1] It was developed as a weight loss drug by Inversago Pharma.^[2][3][4]

Other namesINV-202, MRI-1891

Legal status

• Investigational

CAS Number

• 2712480-46-9

PubChem CID

• 164888943

Quick facts Clinical data, Other names ...

Monlunabant

Clinical data
Other names	INV-202, MRI-1891
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-[(E)-N′-[(Z)-C-[(4S)-5-(4-Chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-N-[4-(trifluoromethyl)phenyl]sulfonylcarbonimidoyl]carbamimidoyl]acetamide
CAS Number	2712480-46-9
PubChem CID	164888943
ChemSpider	128942559
UNII	4G8X27X87A
Chemical and physical data
Formula	C26H22ClF3N6O3S
Molar mass	591.01 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)N/C(=N/C(=N/S(=O)(=O)C1=CC=C(C=C1)C(F)(F)F)/N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4)/N
InChI InChI=1S/C26H22ClF3N6O3S/c1-16(37)32-24(31)33-25(35-40(38,39)21-13-9-19(10-14-21)26(28,29)30)36-15-22(17-5-3-2-4-6-17)23(34-36)18-7-11-20(27)12-8-18/h2-14,22H,15H2,1H3,(H3,31,32,33,35,37)/t22-/m1/s1 Key:GYJPQNPVIJXXTA-JOCHJYFZSA-N

Close

Novo Nordisk’s obesity drug monlunabant showed only modest weight loss in a Phase 2a trial.^[5] The drug was associated with higher rates of mild to moderate neuropsychiatric side effects like anxiety and sleep disturbances.^[6] Suicidal ideations were not reported.